Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Good
|
New words:
activist, allegedly, Alto, Amazon, ascertain, Champaign, closure, comparison, competitor, Connecticut, COVID, curated, decommissioning, degradation, destroy, earnout, ease, Educational, excise, Exhibit, fifteen, IL, Inducement, invasion, landscape, lived, Measurementsto, membership, migrate, migrating, migration, Nominating, occupancy, outlined, overseeing, Palo, promptly, reimplementation, reinstated, revalued, rewarding, smarter, specialist, substantive, syndication, thirty, tone, turmoil, understatement, undiscounted, unplanned, Utah, vendor
Removed:
activation, affiliated, analyze, Brexit, certainty, commit, cure, Customization, deceptive, Fidelity, Francisco, Governor, highest, host, interact, interconnected, Laube, leasing, Lynne, mind, overlapping, percent, phased, placement, predicted, promissory, redundancy, repaid, reseller, rupee, San, Suwanee, turnover, unclear, valid, virtually, Visakhapatnam, voluntary
Filing tables
Filing exhibits
Related press release
Associated CDLX transcripts
CDLX similar filings
Filing view
External links
Exhibit 10.45
AMENDMENT TO
CARDLYTICS, INC.
2022 INDUCEMENT PLAN
A. Cardlytics, Inc., a corporation organized under the laws of the State of Delaware, (the “Company”) established the Company’s 2022 Inducement Plan (the “Plan”);
B. The Plan currently provides for 1,500,000 shares of Common Stock to be reserved for issuance under the Plan; and
C. The Company now wishes to amend the Plan to increase the number of shares of Common Stock reserved for issuance under the Plan to an aggregate of 1,850,000 shares.
Effective immediately, the Plan is amended as follows:
1. The reference to “1,500,000 shares” in Section 3(a) of the Plan is hereby amended to reference “1,850,000 shares”.
2. In all other respects, the Plan will remain the same.
Exhibit 10.45
IN WITNESS WHEREOF, the Company has caused this Amendment to be executed as of January 18, 2023.
CARDLYTICS, INC. | ||
By: /s/ Karim Temsamani | ||
Karim Temsamani | ||
Chief Executive Officer |